Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Inclusion Criteria: * Subjects must provide signed inform consent prior to participation. * BMI between 19,5 y 29 kg/m2. * Normal ocular test in both eyes: IOP \</=21 mmHg. BCVAof \>/=0,8 (20/25)Snellen scale, or \</=0.1 LogMar. * Normal fluorescein Clearance Test in both eyes. * Normal funduscopy in both eyes. Exclusion Criteria: * Pregnant or breastfeeding females or those with a positive pregnancy test or who will not use a medically acceptable contraceptive method from selection and during the study. * Current relevant disease. * Previous chronic processes or with rebound characteristics that could interfere with study according investigator's judgment. * Volunteers who have received pharmacological treatment, including medicinal plants, during the four weeks previous to beginning the study. * Having used corticoids sporadically in the last 30 days whichever the route aof administration, or any med by ocular or nasal administration route. * Case history of hypersensitivity to meds or any other allergic process. * Visual alterations: previous eye surgery, glaucoma, use of lenses, uveitis or ocular surface pathology (dry eye, blepharitis). * Volunteers with visual alteration with more than 3 dioptres in either eye. * Volunteers who has participated in a clinical trial during the past fout months before study entry. * Blood or derivate transfusion during the six previous months to study entry. * Case history of drug or alcohol abuse or dependence. * Positive result in test drug abuse during selection period. * positive serology results to hepatitis B virus(HbsAg), virus C o VIH. * Analytic alterations medically relevant, at investigator's judgement.